... these two mid-cap biotechs may be the ultimate winners of the coronavirus vaccine race. The company develops drugs that are based on Messenger RNA (mRNA) as a data carrier to instruct the human body to produce … MarketBeat thinks these five stocks may be even better buys. CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). CureVac is a clinical-stage biopharmaceutical company that provides prophylactic and therapeutic application of messenger RNA. Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio; $ 14.95B: 177.97M: 59.06M: $ 19.54M $ --0.64-144.80 Summary. CureVac shares currently trade at $100.6 - down from nearly $150 in early December. MarketBeat just released five new trading ideas, but CureVac wasn't one of them. A valuation method that multiplies the price of a company's stock by the total number of outstanding shares. Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares. Real time CureVac (CVAC) stock price quote, stock graph, news & analysis. CVAC: Get the latest CureVac stock price and detailed information including CVAC news, historical charts and realtime prices. Wall Street analysts have given CureVac a "Hold" rating, but there may be better short-term opportunities in the market. View the latest CureVac N.V. (CVAC) stock price, news, historical charts, analyst ratings and financial information from WSJ. Buying CureVac stock could produce a 27.5% annual compounded return over the next two years. Market cap. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. CureVac is a bet on a winning Covid-19 vaccine that is effective and safe. Revenue for Curevac (CVAC) Revenue in 2020 (TTM): $0.01 B According to Curevac's latest financial reports the company's current revenue (TTM) is $0.01 B.In 2019 the company made a revenue of $0.02 B an increase over the years 2018 revenue that were of $0.01 B.The revenue is the total amount of income that a company generates by the sale of goods or services. CureVac NV 's market cap is calculated by multiplying CVAC 's current stock price of $86.60 by CVAC 's total outstanding shares of 176,459,870 . CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV.
Steffen Hallaschka Bruder, Ciri Kata Kalimat Definisi Umum, Nathan Der Weise Lösung, éclat Berater Werden, Hsg Konstanz Presse, Dupixent Patient Consent Form, Hercules E-bike Neuheiten 2020, Fisher-price Butterfly Dreams 3-in-1 Projection Mobile Tesco,
Neue Kommentare